Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations
2006
The relationship between prognostic and predictive factors in the management of breast cancer
1998
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
EGFR Antagonists in Cancer Treatment
2008 Standout
The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial
1992
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
2009 Standout
A Rationale for the Reinitiation of Adjuvant Tamoxifen Therapy in Women Receiving Fewer than 5 Years of Therapy
2002
Adjuvant Therapy of Premenopausal and Menopausal High-Risk Breast Cancer Patients: Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B
1988
The biology and management of non-small cell lung cancer
2018 StandoutNature
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Lung Cancer
2008 Standout
Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial
2001
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Adjuvant therapy for breast cancer — results from the USA consensus conference
2001
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
2011 Standout
Pathological prognostic factors in breast cancer
1999 Standout
Measuring inconsistency in meta-analyses
2003 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Oesophageal carcinoma
2013 Standout
A Translational View of the Molecular Pathogenesis of Lung Cancer
2007
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
2005 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
1990
Where next for gefitinib in patients with lung cancer?
2006
Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis
2011 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Annual hazard rates of recurrence for breast cancer after primary therapy.
1996
Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis
2007
Addicted to Death
2004
Adjuvant tamoxifen: how long before we know how long?
1998
Breast cancer adjuvant therapy
1990
Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy
1997 Standout
Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer
1991
Does tumour dormancy offer a therapeutic target?
2010
Strategies for optimizing combinations of molecularly targeted anticancer agents
2006
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
VEGF Inhibition and Renal Thrombotic Microangiopathy
2008 Standout
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Tumor Angiogenesis
2008 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
2007
Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer
2007
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
2000
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
2003 Standout
Regulatory T Cells and Human Disease
2020 StandoutNobel
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
2009
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
1992 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
2001 Standout
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
2007
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
2001
Metabolic reprogramming and cancer progression
2020 StandoutScience
Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
2006
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
2001 StandoutNobel
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer
2004 Standout
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
2006
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
2002 Standout
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
2007
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
2014 Standout
Tamoxifen for early breast cancer: an overview of the randomised trials
1998 Standout
Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
2005
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse
2006
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
2007
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
2005 Standout
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
2005 Standout
Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93
2006
Works of R Gray being referenced
Postchemotherapy Adjuvant Tamoxifen Therapy Beyond Five Years in Patients With Lymph Node-Positive Breast Cancer
1996
Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An eastern cooperative oncology group trial
1990
Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients.
1993
Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599
2005
Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076).
1992
Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer.
1986
O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599
2005